Cervene (Nalmefene) in acute ischemic stroke: Final results of a phase III efficacy study

Wayne Clark, Eric C. Raps, David C. Tong, Roger E. Kelly

Research output: Contribution to journalArticle

78 Citations (Scopus)

Abstract

Background and Purpose - The goals of the present study were to assess the efficacy and safety of nalmefene (Cervene) in patients with acute (≤6 hours) ischemic stroke and to investigate the safety of combined recombinant tissue plasminogen activator and nalmefene in a separate subset of patients. Nalmefene, an opioid antagonist with relative κ receptor selectivity, has shown neuroprotective effects in multiple experimental central nervous system injury and ischemic models. Results from an earlier phase II study in patients with acute ischemic stroke suggested that nalmefene was safe and tolerable and may be effective for patients

Original languageEnglish (US)
Pages (from-to)1234-1239
Number of pages6
JournalStroke
Volume31
Issue number6
StatePublished - Jun 2000

Fingerprint

Stroke
Nervous System Trauma
Safety
Narcotic Antagonists
Neuroprotective Agents
Tissue Plasminogen Activator
Central Nervous System
nalmefene

Keywords

  • Narcotic antagonists
  • Stroke
  • Therapy

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Neuroscience(all)

Cite this

Clark, W., Raps, E. C., Tong, D. C., & Kelly, R. E. (2000). Cervene (Nalmefene) in acute ischemic stroke: Final results of a phase III efficacy study. Stroke, 31(6), 1234-1239.

Cervene (Nalmefene) in acute ischemic stroke : Final results of a phase III efficacy study. / Clark, Wayne; Raps, Eric C.; Tong, David C.; Kelly, Roger E.

In: Stroke, Vol. 31, No. 6, 06.2000, p. 1234-1239.

Research output: Contribution to journalArticle

Clark, W, Raps, EC, Tong, DC & Kelly, RE 2000, 'Cervene (Nalmefene) in acute ischemic stroke: Final results of a phase III efficacy study', Stroke, vol. 31, no. 6, pp. 1234-1239.
Clark, Wayne ; Raps, Eric C. ; Tong, David C. ; Kelly, Roger E. / Cervene (Nalmefene) in acute ischemic stroke : Final results of a phase III efficacy study. In: Stroke. 2000 ; Vol. 31, No. 6. pp. 1234-1239.
@article{d2c8bff34b3c4e0db564aafc32fa7824,
title = "Cervene (Nalmefene) in acute ischemic stroke: Final results of a phase III efficacy study",
abstract = "Background and Purpose - The goals of the present study were to assess the efficacy and safety of nalmefene (Cervene) in patients with acute (≤6 hours) ischemic stroke and to investigate the safety of combined recombinant tissue plasminogen activator and nalmefene in a separate subset of patients. Nalmefene, an opioid antagonist with relative κ receptor selectivity, has shown neuroprotective effects in multiple experimental central nervous system injury and ischemic models. Results from an earlier phase II study in patients with acute ischemic stroke suggested that nalmefene was safe and tolerable and may be effective for patients",
keywords = "Narcotic antagonists, Stroke, Therapy",
author = "Wayne Clark and Raps, {Eric C.} and Tong, {David C.} and Kelly, {Roger E.}",
year = "2000",
month = "6",
language = "English (US)",
volume = "31",
pages = "1234--1239",
journal = "Stroke",
issn = "0039-2499",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - Cervene (Nalmefene) in acute ischemic stroke

T2 - Final results of a phase III efficacy study

AU - Clark, Wayne

AU - Raps, Eric C.

AU - Tong, David C.

AU - Kelly, Roger E.

PY - 2000/6

Y1 - 2000/6

N2 - Background and Purpose - The goals of the present study were to assess the efficacy and safety of nalmefene (Cervene) in patients with acute (≤6 hours) ischemic stroke and to investigate the safety of combined recombinant tissue plasminogen activator and nalmefene in a separate subset of patients. Nalmefene, an opioid antagonist with relative κ receptor selectivity, has shown neuroprotective effects in multiple experimental central nervous system injury and ischemic models. Results from an earlier phase II study in patients with acute ischemic stroke suggested that nalmefene was safe and tolerable and may be effective for patients

AB - Background and Purpose - The goals of the present study were to assess the efficacy and safety of nalmefene (Cervene) in patients with acute (≤6 hours) ischemic stroke and to investigate the safety of combined recombinant tissue plasminogen activator and nalmefene in a separate subset of patients. Nalmefene, an opioid antagonist with relative κ receptor selectivity, has shown neuroprotective effects in multiple experimental central nervous system injury and ischemic models. Results from an earlier phase II study in patients with acute ischemic stroke suggested that nalmefene was safe and tolerable and may be effective for patients

KW - Narcotic antagonists

KW - Stroke

KW - Therapy

UR - http://www.scopus.com/inward/record.url?scp=0034034434&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034034434&partnerID=8YFLogxK

M3 - Article

C2 - 10835438

AN - SCOPUS:0034034434

VL - 31

SP - 1234

EP - 1239

JO - Stroke

JF - Stroke

SN - 0039-2499

IS - 6

ER -